Literature DB >> 29061462

Predicting Prognosis of Patients with Chronic Subdural Hematoma: A New Scoring System.

Churl-Su Kwon1, Omar Al-Awar2, Oliver Richards3, Alane Izu4, Givi Lengvenis5.   

Abstract

OBJECTIVE: Chronic subdural hematoma (CSDH) is a commonly encountered neurosurgical pathology that frequently requires operative intervention. With an increasing ageing demographic, more elderly and comorbid patients will present with symptomatic CSDH. This study evaluated clinical and radiologic factors to create a scoring system to aid prognostication.
METHODS: A cohort of patients undergoing evacuation of CSDH at a single institution was established from 2010 to 2015. Primary endpoint was a dichotomized score on a modified Rankin Scale score at 1-year follow-up (favorable outcome score 0-1; unfavorable outcome score 2-6). Logistic regression analyses were performed to model determinants related to outcome. A prediction rule for diagnosing poor postoperative prognosis with unfavorable modified Rankin Scale score was developed with the obtained results.
RESULTS: Logistic regression analyses showed that age >75 years, midline shift >10 mm, and hematoma thickness >30 mm were significantly associated with unfavorable outcome (age >75 years: odds ratio [OR] 0.01, 95% confidence interval [CI] 0.001-0.01; midline shift 11-20 mm: OR 0.18, 95% CI 0.04-0.88; midline shift >20 mm: OR 0.03, 95% CI 0.002-0.41; hematoma thickness >30 mm: OR 0.07, 95% CI 0.01-0.46). A scoring system was designed using the final fitted multivariate model. A minimum score of 3 is feasible, indicating worst prognosis, and maximum score of 13 is feasible, indicating best prognosis. A score of ≥9 showed favorable outcome. Receiver operating characteristic curves were constructed to predict favorable versus unfavorable outcomes with the sensitivity analysis yielding an excellent model discrimination with an area under curve of 0.95, 95% CI 0.92-0.98.
CONCLUSIONS: A scoring system has been devised to predict outcome, which can aid in the necessity of surgery in certain patient demographics.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic subdural hematoma; Prognosis; Scoring system

Mesh:

Year:  2017        PMID: 29061462     DOI: 10.1016/j.wneu.2017.10.058

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Exploratory Analysis of Preoperative and Postoperative Risk Stratification Tools to Identify Acute Kidney and Myocardial Injury in Patients Undergoing Surgery for Chronic Subdural Haematoma.

Authors:  Daniel J Stubbs; Benjamin M Davies; Rowan Burnstein; Alexis J Joannides; Ari Ercole
Journal:  J Neurosurg Anesthesiol       Date:  2021-08-23       Impact factor: 3.969

2.  Identification of Prognostic Factors in Surgically Treated Patients with Acute Epidural Hematoma.

Authors:  Koki Onodera; Tomoya Kamide; Tatsuki Kimura; Shinya Tabata; Toshiki Ikeda; Yuichiro Kikkawa; Hiroki Kurita
Journal:  Asian J Neurosurg       Date:  2020-08-28

3.  Development and validation of a prognostic prediction model for antithrombotic-related chronic subdural hematoma in patients with recent acute myocardial infarction.

Authors:  Peng Zhou; Jindong Wan; Fei Ran; Feng Gao; Dachun Yang; Xiaozhen Dai; Yun Sun; Peijian Wang
Journal:  Cardiovasc Diagn Ther       Date:  2020-12

4.  External validation of prognostic models predicting outcome after chronic subdural hematoma.

Authors:  Dana C Holl; Ana Mikolic; Jurre Blaauw; Roger Lodewijkx; Merijn Foppen; Korné Jellema; Niels A van der Gaag; Heleen M den Hertog; Bram Jacobs; Joukje van der Naalt; Dagmar Verbaan; K H Kho; C M F Dirven; Ruben Dammers; Hester F Lingsma; David van Klaveren
Journal:  Acta Neurochir (Wien)       Date:  2022-05-03       Impact factor: 2.816

5.  A matter of frailty: the modified Subdural Hematoma in the Elderly (mSHE) score.

Authors:  Silvia Hernández-Durán; Daniel Behme; Veit Rohde; Christian von der Brelie
Journal:  Neurosurg Rev       Date:  2021-07-06       Impact factor: 2.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.